FDA-Approved Drug Shows Promise in Treating Rare Liver Cancer

Immunotherapy, a treatment that harnesses the body’s own immune system to fight cancer, has historically shown limited success against fibrolamellar carcinoma, a rare and often fatal liver cancer primarily affecting children and young adults. Still, a new study reveals that an existing FDA-approved drug, AMD3100, may overcome barriers to immunotherapy, offering a potential new treatment option for patients with this challenging disease.

Understanding Fibrolamellar Carcinoma

Fibrolamellar carcinoma accounts for up to 2% of all liver cancers . It often has no cure and is frequently detected after it has already spread (metastasized), leading to a poor prognosis .

Why Immunotherapy Has Struggled with Fibrolamellar Carcinoma

Researchers at Cornell University discovered that fibrolamellar tumors create a unique microenvironment that prevents the body’s T cells from reaching and attacking the cancer cells. This process, known as T-cell exclusion, essentially traps immune cells away from the tumor . Immune checkpoint inhibitors, a common type of immunotherapy, work by activating T cells and directing them to the tumor core, but are ineffective when T cells are excluded.

How AMD3100 Could Change the Treatment Landscape

The study found that AMD3100 can prevent tumors from sequestering T cells, allowing them to infiltrate the tumor and attack cancer cells . Researchers at the University of Washington confirmed these findings by testing AMD3100 on patient tumor slices, demonstrating that it effectively mobilized T cells into the tumor core. Combining AMD3100 with immune checkpoint inhibition further enhanced T cell activation and increased the death of tumor cells .

The Role of Single-Nucleus Transcriptomics

The research team utilized single-nucleus transcriptomics, a cutting-edge technology, to analyze individual cell nuclei within the tumor tissue. This allowed them to identify which genes were active in each cell and understand how the tumor microenvironment was preventing T cell infiltration .

Future Directions and Clinical Trials

Researchers are now working to initiate clinical trials to evaluate the effectiveness of AMD3100 in treating fibrolamellar carcinoma. A significant advantage is that AMD3100 is already FDA-approved for other conditions, which could expedite the clinical trial process .

Key Takeaways

• Fibrolamellar carcinoma is a rare and aggressive liver cancer with limited treatment options.
• T-cell exclusion prevents immunotherapy from effectively targeting fibrolamellar tumors.
• AMD3100, an existing FDA-approved drug, shows promise in overcoming T-cell exclusion and enhancing immunotherapy.
• Clinical trials are planned to evaluate the effectiveness of AMD3100 in treating this cancer.

Reference: Carter JA, Dickerson LK, Stephanou A, et al. Overcoming CXCR4-mediated T-cell exclusion potentiates antitumor cytotoxicity in fibrolamellar carcinoma. Gastroenterol. 2026:S0016508525061219. Doi: 10.1053/j.gastro.2025.10.006